Conduit Pharmaceuticals Inc. Share Price

Equities

CDT

US20678X1063

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 25/06/2024 BST 5-day change 1st Jan Change
1.23 USD -15.17% Intraday chart for Conduit Pharmaceuticals Inc. -22.64% -72.97%
Sales 2022 - Sales 2023 - Capitalization 331M 26.12B
Net income 2022 -4M -315M Net income 2023 - 0 EV / Sales 2022 -
Net Debt 2022 2.01M 158M Net cash position 2023 3.24M 256M EV / Sales 2023 -
P/E ratio 2022 *
-
P/E ratio 2023
-51 x
Employees 7
Yield 2022 *
-
Yield 2023
-
Free-Float 13.35%
More Fundamentals * Assessed data
Dynamic Chart
1 day-15.17%
1 week-22.64%
Current month-59.54%
1 month-59.41%
3 months-63.28%
6 months-75.60%
Current year-72.97%
More quotes
1 week
1.23
Extreme 1.23
1.81
1 month
1.23
Extreme 1.23
3.27
Current year
1.23
Extreme 1.23
5.29
1 year
0.95
Extreme 0.95
25.00
3 years
0.95
Extreme 0.95
25.00
5 years
0.95
Extreme 0.95
25.00
10 years
0.95
Extreme 0.95
25.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 21/09/23
Director of Finance/CFO 55 30/09/21
Members of the board TitleAgeSince
Chairman 69 21/09/23
Director/Board Member 50 21/09/23
Director/Board Member 62 21/09/23
More insiders
Date Price Change Volume
25/06/24 1.23 -15.17% 61 201
24/06/24 1.45 -7.05% 55,239
21/06/24 1.56 +6.85% 219,157
20/06/24 1.46 -8.18% 80,899
18/06/24 1.59 -5.92% 108,942

Delayed Quote Nasdaq, June 25, 2024 at 09:00 pm

More quotes
Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company’s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto’s Thyroiditis. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis (HT and Graves’ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto’s Thyroiditis and Graves’ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).
More about the company